A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours

This study is testing a new experimental medication called AZD4956 to see if it is safe and effective for treating certain types of solid tumors. By focusing on cancers with specific genetic repair issues, researchers hope to find a better way to treat advanced or spread-out cancer.

This study is for adults with advanced or metastatic solid tumors that have specific genetic changes known as homologous recombination repair (HRR) deficiencies. You must be physically active enough to handle treatment and have stable organ function, while not having certain conditions like untreated brain metastases or active infections.

Participants will receive the study medication, either alone or combined with another drug called Saruparib, to see how the body handles it and if it helps fight the cancer. You will have regular check-ups and health assessments to monitor your safety and see how your body responds to the treatment.

The study is currently recruiting patients at medical centers in New York, Rhode Island, and Texas. It is an active, ongoing trial designed to learn more about this potential new therapy.